Annovis Bio Inc (ANVS)

Mar 27, 2025, 4:30 PM EDT - 27 days ago

Annovis Bio, Inc. Receives Continued Listing Standard Notice From the NYSE

Mar 25, 2025, 8:00 AM EDT - 4 weeks ago

Annovis to Attend AD/PD™ 2025 with Extensive Scientific Program

Mar 21, 2025, 5:05 PM EDT - 4 weeks ago

Annovis Provides Corporate Updates and Reports Fourth Quarter and Fiscal Year 2024 Financial Results

Mar 11, 2025, 8:00 AM EDT - 6 weeks ago

Annovis Joins Experts at Drug Development Summit to Redefine Parkinson's Treatment

Feb 19, 2025, 8:30 AM EST - 2 months ago

Annovis to Host Patients' Live Forum on February 27, 2025

Feb 7, 2025, 8:00 AM EST - 2 months ago

Annovis to Present at Oppenheimer's 35th Annual Healthcare Life Sciences Conference

Feb 5, 2025, 8:00 AM EST - 2 months ago

Annovis Announces First Patients Entered into Pivotal Phase 3 Study of Buntanetap for Early Alzheimer's Disease

Feb 4, 2025, 4:31 PM EST - 2 months ago

Annovis Bio, Inc. Announces Closing of $21 Million Public Offering

Feb 3, 2025, 6:22 AM EST - 2 months ago

Annovis Bio, Inc. Announces Pricing of $21 Million Public Offering

Jan 31, 2025, 8:14 PM EST - 2 months ago

Annovis Bio, Inc. Announces Proposed Public Offering

Jan 14, 2025, 8:00 AM EST - 3 months ago

Annovis Granted U.S. Patent for Treatment and Prevention of Acute Brain or Nerve Injuries Securing Global Protection

Dec 5, 2024, 8:30 AM EST - 4 months ago

Annovis CEO Showcases Groundbreaking Advances in Neurodegenerative Disease Treatment on Today's Marketplace

Dec 4, 2024, 2:21 PM EST - 5 months ago

/C O R R E C T I O N -- Today's Marketplace/

Nov 25, 2024, 8:00 AM EST - 5 months ago

Annovis to Host Year-End Investor Webcast on December 11, 2024

Oct 31, 2024, 8:00 AM EDT - 6 months ago

IBN Announces Latest Episode of The BioMedWire Podcast Featuring Dr. Maria Maccecchini, CEO of Annovis Bio

Oct 15, 2024, 8:00 AM EDT - 6 months ago

FDA Clears Annovis to Launch Pivotal Phase 3 Alzheimer's Studies, Paving the Way to NDAs

Oct 3, 2024, 8:30 AM EDT - 7 months ago

Annovis Bio Inc. (NYSE: ANVS) Leading Way in Development of Safe, Effective Drugs for Neurodegenerative Diseases

Oct 2, 2024, 8:30 AM EDT - 7 months ago

Annovis Bio Inc. (NYSE: ANVS) Research Points to Potential Future Breakthroughs in AD Space Through Innovative Combinations

Sep 5, 2024, 8:00 AM EDT - 8 months ago

Annovis Bio (NYSE: ANVS) to Present at H.C. Wainwright 26th Annual Global Investment Conference

Aug 6, 2024, 8:00 AM EDT - 9 months ago

Annovis' Lead Compound Enhances Cognition Synergistically with GLP-1 Agonist

Jul 24, 2024, 8:00 AM EDT - 9 months ago

Annovis Bio Secures U.S. Patent for Treatment of Acute Traumatic Brain Injury with Buntanetap

Jul 2, 2024, 4:13 PM EDT - 10 months ago

Annovis stock more than doubled on Tuesday: what happened?

Jul 2, 2024, 1:57 PM EDT - 10 months ago

Annovis Bio's stock rockets 119% after reporting positive data in Parkinson's disease trial

Jun 26, 2024, 8:00 AM EDT - 10 months ago

Annovis Bio Files Patent for New Composition of Matter for Buntanetap

Jun 11, 2024, 8:00 AM EDT - 11 months ago

Annovis Bio's Buntanetap Found Safe and Effective in High-Risk Alzheimer's Patients

May 21, 2024, 7:30 AM EDT - 1 year ago

Annovis Announces New Publication in a Peer-Reviewed Journal

May 16, 2024, 7:02 PM EDT - 1 year ago

Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Announces Investigation of Annovis Bio, Inc. (ANVS) on Behalf of Investors

May 16, 2024, 3:09 PM EDT - 1 year ago

The Law Offices of Frank R. Cruz Announces Investigation of Annovis Bio, Inc. (ANVS) on Behalf of Investors

May 13, 2024, 7:30 AM EDT - 1 year ago

Annovis Bio Provides Corporate Updates and Announces First Quarter 2024 Financial Results

May 9, 2024, 8:43 PM EDT - 1 year ago

Annovis, Anavex, And Cassava Sciences: Trying To Box Oneself Out Of The Alzheimer's Box

SAVA AVXL

May 9, 2024, 7:30 AM EDT - 1 year ago

Annovis Announces Unblinding of the Buntanetap Phase III Data in Parkinson's Disease

May 6, 2024, 7:30 AM EDT - 1 year ago

Annovis Bio CEO Maria Maccecchini Issues Letter to Stockholders

Apr 29, 2024, 10:30 AM EDT - 1 year ago

Annovis Bio reports positive results in mid-stage Alzheimer's treatment trial

Apr 29, 2024, 10:10 AM EDT - 1 year ago

Annovis Bio Announces Statistically Significant Phase II/III Data in Patients With Early Alzheimer's Disease

Apr 2, 2024, 7:30 AM EDT - 1 year ago

Annovis Bio Provides Corporate Updates and Reports Fourth Quarter and Full Year 2023 Financial Results

Apr 1, 2024, 8:00 AM EDT - 1 year ago

Annovis Announces Publication That Supports Understanding of Buntanetap's Mechanism of Action in Humans

Mar 20, 2024, 7:30 AM EDT - 1 year ago

Annovis Bio Provides Data Announcement Update for the Phase II/III Study of Buntanetap in Alzheimer's Disease

Feb 27, 2024, 8:00 AM EST - 1 year ago

Annovis Bio Announces Participation in Forum Discussion at AD/PD™ 2024

Feb 14, 2024, 7:30 AM EST - 1 year ago

Annovis Bio Announces Last Patient Last Visit in the Phase II/III Study of Buntanetap in Alzheimer's Disease

Feb 12, 2024, 9:06 AM EST - 1 year ago

Annovis: Potentially Encouraging Anecdotes, Weighing Phase 3 Parkinson's Prospects

Jan 30, 2024, 8:00 AM EST - 1 year ago

Annovis Bio Announces the Filing of New Patent Application for Treatment of Mental Illnesses Expanding the Company's Portfolio

Jan 24, 2024, 8:00 AM EST - 1 year ago

Annovis Bio Refines Timeline for Parkinson's Phase III Study Data Announcement

Dec 11, 2023, 1:00 PM EST - 1 year ago

Annovis Bio to Participate in the 139th Yale CEO Summit

Dec 5, 2023, 7:30 AM EST - 1 year ago

Annovis Bio Announces Last Patient Last Visit in the Phase III Study of Buntanetap in Parkinson's Disease

Dec 5, 2023, 3:58 AM EST - 1 year ago

Alzheimer's Disease Drug Development: Another Lost Year

AVXL BIIB INMB LLY SAVA

Dec 1, 2023, 7:30 AM EST - 1 year ago

Annovis Bio Appoints Andrew Walsh as Vice President Finance

Nov 27, 2023, 7:30 AM EST - 1 year ago

Annovis Bio Announces Full Enrollment of Its Phase II/III Alzheimer's Disease Trial, Exceeding Original Projections

Nov 8, 2023, 5:00 PM EST - 1 year ago

Annovis Bio Announces Third Quarter 2023 Financial Results and Provides Corporate Update

Nov 2, 2023, 7:30 AM EDT - 1 year ago

Annovis Bio Measures Novel Biomarkers in Plasma of Parkinson's Patients